Meeting
2022 ASCO Annual Meeting
Longitudinal immunological responses of COVID-19 vaccination in patients with solid tumors on active treatment: A pilot study.
Authors
Lifen Cao
University Hospitals at Cleveland Medical Center, Cleveland, OH
Lifen Cao , Shelby Rose Kopp , Patricia A. Rayman , Naji Mallat , Yan Leyfman , James Michael Martin , Jennifer Eva Selfridge , C. Marcela Diaz-Montero , Alberto J. Montero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Prevention of Primary and Secondary Malignancies
Clinical Trial Registration Number
NCT05238467
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS10618)
DOI
10.1200/JCO.2022.40.16_suppl.TPS10618
Abstract #
TPS10618
Poster Bd #
490a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
The effect of corticosteroid on immunogenicity of SARS-CoV-2 vaccines in solid cancer patients.
First Author: Chayanee Samdaengpan
Poster
2024 ASCO Annual Meeting
A phase 3 study to evaluate efficacy and safety of VYD222, an IgG1 monoclonal antibody for prevention of COVID-19 (CANOPY): Subset analysis of participants with significant immune compromise in the setting of solid tumor or hematologic malignancies.
First Author: Myra Wooley Popejoy
Poster
2023 ASCO Annual Meeting
Immunogenicity after COVID-19 vaccination in patients with solid tumor and hospital staff: A prospective single-center observational study.
First Author: Yuki Katsuya
Poster
2023 ASCO Annual Meeting
Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors.
First Author: Raffit Hassan